The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
Illumina also said it is developing a regulated version of its high-throughput NovaSeq system to address growing demand for a diagnostic platform with higher throughput.
Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.
Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.
